RxDoctor Payments Data

van Meeks, MD

Internal Medicine · Paducah, KYNPI 1255574984

Payments from drug & device makers

$6,013in general payments, 2019–2025

Across 421 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$744
  • AbbVie$412
  • Pfizer$359
  • Boehringer Ingelheim$334
  • Takeda Pharmaceuticals U.S.A., Inc.$326
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,013100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,013 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$108,548
Medicare patients
202
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$63,990
OzempicSemaglutide32$46,137
JardianceEmpagliflozin30$30,583
FarxigaDapagliflozin Propanediol14$22,337
Spiriva HandihalerTiotropium Bromide20$20,628
TrulicityDulaglutide11$19,725
EntrestoSacubitril/Valsartan16$14,069
MounjaroTirzepatide12$13,509
MyrbetriqMirabegron11$8,523
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$6,062
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen270$4,353
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$4,009
DexilantDexlansoprazole12$3,482
Bupropion XlBupropion Hcl89$2,912
Rosuvastatin Calcium254$2,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$359$63,99051 claims
Novo NordiskOzempic, Levemir$1,129$47,30143 claims
Lilly USA, LLCTrulicity, Mounjaro$744$33,23523 claims
Boehringer IngelheimJardiance$334$30,58330 claims
AstraZenecaFarxiga$149$22,33714 claims
NovartisEntresto$89$14,06916 claims
Astellas Pharma US IncMyrbetriq$117$8,52311 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$326$3,48212 claims
AbbVieSynthroid$412$2,48647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →